{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:29:31Z","timestamp":1793946571170,"version":"4.8.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jns.2026.125884","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:37:17Z","timestamp":1774021037000},"page":"125884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comment on \u201cCost-effectiveness analysis of high-efficacy drugs used in the treatment of multiple sclerosis in a large health insurance provider in Brazil\u201d"],"prefix":"10.1016","volume":"485","author":[{"given":"Miduthuru","family":"Sukumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabilan","family":"Annadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supplement","key":"10.1016\/j.jns.2026.125884_bb0005","article-title":"Cost-effectiveness analysis of high-efficacy drugs used in the treatment of multiple sclerosis in a large health insurance provider in Brazil","volume":"480","author":"Fiebrantz","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2026.125884_bb0010","doi-asserted-by":"crossref","DOI":"10.1007\/s40273-025-01539-3","article-title":"Cost-consequence analysis of natalizumab compared with other high-efficacy treatments in patients with relapsing\u2013remitting multiple sclerosis","author":"Prosperini","year":"2025","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jns.2026.125884_bb0015","article-title":"Prospective inter-individual analysis of quality-adjusted life years (QALYs) in brain tumor patients: a comprehensive assessment of health preferences","author":"H\u00f6nikl","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jns.2026.125884_bb0020","series-title":"Real-World Data and Cardiovascular Medications: Diving into Sex Differences","author":"Kiss","year":"2025"},{"key":"10.1016\/j.jns.2026.125884_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106724","article-title":"The real-world efficacy of cladribine tablets and treatment persistence in people with highly active relapsing multiple sclerosis in Finland \u2013 a follow-up study after four years of observation","author":"Rauma","year":"2025","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26001668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26001668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:52:13Z","timestamp":1793944333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26001668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":5,"alternative-id":["S0022510X26001668"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125884","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comment on \u201cCost-effectiveness analysis of high-efficacy drugs used in the treatment of multiple sclerosis in a large health insurance provider in Brazil\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125884"}}